|
|
Prepublished online as a Blood First Edition Paper on August 29, 2002; DOI 10.1182/blood-2002-02-0545.
Submitted March 1, 2002
Accepted May 14, 2002
Imatinib mesylate therapy in newly-diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
Hagop M Kantarjian*, Jorge E Cortes, Susan O'Brien, Francis Giles, Guillermo Garcia-Manero, Stefan Faderl, Deborah Thomas, Sima Jeha, Mary Beth Rios, Laurie Letvak, Kathy Bochinski, Ralph Arlinghaus, and Moshe Talpaz
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Novartis Pharmaceuticals, East Hanover, NJ, USA
Department of Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Department of Bioimmunotherapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
* Corresponding author; email: hkantarj{at}mdanderson.org.
Fifty patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) in early chronic phase received imatinib mesylate 400 mg orally daily. After a median follow-up of 9 months, 49 patients (98%) achieved a complete hematologic response and 45 patients (90%) achieved a major cytogenetic response, complete in 36 patients (72%). Compared with similar patients who received interferon alpha regimens, those receiving imatinib mesylate had higher incidences of complete and major (Ph <35%) cytogenetic responses at 3 months (34% and 74% versus 1-4% and 9-24%, respectively), 6 months (52% and 80% versus 3-7% and 11-28%, respectively), and 9 months (60% and 77% versus 5-11% and 14-30%, respectively) (p values <0.001). Competitive quantitative polymerase chain reaction (QPCR) studies at 9 months showed a median QPCR value (ratio of BCR-ABL/ABL transcripts x 100) of 0.59% overall, and of 0.24% (range 0.001% to 29.5%) for complete cytogenetic response.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. M. Kantarjian, J. Shan, D. Jones, S. O'Brien, M. B. Rios, E. Jabbour, and J. Cortes
Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
J. Clin. Oncol.,
August 1, 2009;
27(22):
3659 - 3663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, et al.
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
Blood,
November 15, 2008;
112(10):
3965 - 3973.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome
Haematologica,
May 1, 2008;
93(5):
770 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, L. V. Abruzzo, S. O'Brien, G. Garcia-Manero, S. Verstovsek, J. Shan, M. B. Rios, and J. Cortes
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Blood,
October 15, 2007;
110(8):
2991 - 2995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Samanta, H. Lin, T. Sun, H. Kantarjian, and R. B. Arlinghaus
Janus Kinase 2: A Critical Target in Chronic Myelogenous Leukemia.
Cancer Res.,
July 1, 2006;
66(13):
6468 - 6472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ault, H. Kantarjian, S. O'Brien, S. Faderl, M. Beran, M. B. Rios, C. Koller, F. Giles, M. Keating, M. Talpaz, et al.
Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib
J. Clin. Oncol.,
March 1, 2006;
24(7):
1204 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Golemovic, S. Verstovsek, F. Giles, J. Cortes, T. Manshouri, P. W. Manley, J. Mestan, M. Dugan, L. Alland, J. D. Griffin, et al.
AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia
Clin. Cancer Res.,
July 1, 2005;
11(13):
4941 - 4947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cortes, M. Talpaz, S. O'Brien, D. Jones, R. Luthra, J. Shan, F. Giles, S. Faderl, S. Verstovsek, G. Garcia-Manero, et al.
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Clin. Cancer Res.,
May 1, 2005;
11(9):
3425 - 3432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Quintas-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, M. B. Rios, K. Hayes, A. Glassman, B. N. Bekele, et al.
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
Blood,
March 15, 2005;
105(6):
2281 - 2286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. W. Dewald, M. L. Litzow, J. Cortes, M. J. Mauro, M. Talpaz, and H. M. Kantarjian
Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment
Mayo Clin. Proc.,
March 1, 2005;
80(3):
390 - 402.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. D. Unwin, D. W. Sternberg, Y. Lu, A. Pierce, D. G. Gilliland, and A. D. Whetton
Global Effects of BCR/ABL and TEL/PDGFR{beta} Expression on the Proteome and Phosphoproteome: IDENTIFICATION OF THE RHO PATHWAY AS A TARGET OF BCR/ABL
J. Biol. Chem.,
February 25, 2005;
280(8):
6316 - 6326.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tomoda, J.-y. Kato, E. Tatsumi, T. Takahashi, Y. Matsuo, and N. Yoneda-Kato
The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression
Blood,
January 15, 2005;
105(2):
775 - 783.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Martinelli, G. Rosti, E. Trabacchi, N. Testoni, S. Bassi, M. Amabile, S. Soverini, F. Castagnetti, D. Cilloni, et al.
Imatinib and pegylated human recombinant interferon-{alpha}2b in early chronic-phase chronic myeloid leukemia
Blood,
December 15, 2004;
104(13):
4245 - 4251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, J. E. Cortes, S. O'Brien, R. Luthra, F. Giles, S. Verstovsek, S. Faderl, D. Thomas, G. Garcia-Manero, M. B. Rios, et al.
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}
Blood,
October 1, 2004;
104(7):
1979 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Thomas, S. Faderl, J. Cortes, S. O'Brien, F. J. Giles, S. M. Kornblau, G. Garcia-Manero, M. J. Keating, M. Andreeff, S. Jeha, et al.
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
Blood,
June 15, 2004;
103(12):
4396 - 4407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Calabretta and D. Perrotti
The biology of CML blast crisis
Blood,
June 1, 2004;
103(11):
4010 - 4022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, F. Giles, M. B. Rios, J. Shan, L. Letvak, D. Thomas, et al.
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
Blood,
April 15, 2004;
103(8):
2873 - 2878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, M. L. Hensley, I. Gathmann, A. E. Bolton, I. C. van Hoomissen, J. M. Goldman, et al.
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
N. Engl. J. Med.,
October 9, 2003;
349(15):
1423 - 1432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
